First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia

Read More

Ryvu Therapeutics Reports 2020 Half-Year Financial Results

Read More

Ryvu Therapeutics to present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

Read More

Ryvu Therapeutics raised over USD 36 million from its share issue

Read More

The share issue price in Ryvu Therapeutics public offering set at PLN 60

Read More

Ryvu Therapeutics shareholders have approved a new share issue. Book-building starts today.

Read More

Ryvu Therapeutics Reports First Quarter 2020 Financial Results

Read More

Ryvu Therapeutics signs a grant agreement for the development of targeted immuno-oncology therapy

Read More

NodThera, Ryvu spin-off company, secures £44.5million ($54.5million) Series B Financing

Read More

Ryvu Therapeutics has completed the construction of the R&D Center for Innovative Drugs

Read More